Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
DOI

10.1097/TP.0b013e318210de6b

Type

Journal article

Journal

Transplantation

Publication Date

27/04/2011

Volume

91

Pages

e59 - e61

Keywords

Acute Disease, Alemtuzumab, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm, Biomarkers, Chemokine CXCL10, Chemokine CXCL9, Graft Rejection, Humans, Immunosuppressive Agents, Kidney Transplantation, Preoperative Period, Recombinant Fusion Proteins, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome